Results 11 to 20 of about 2,782 (157)

Amylin receptor subunit interactions are modulated by agonists and determine signaling [PDF]

Science Signaling
Abstract Three amylin receptors (AMYRs) mediate the metabolic actions of the peptide hormone amylin and are drug targets for diabetes and obesity. AMY 1 R, AMY 2 R, and AMY 3 R are heterodimers consisting of the
Nevin Lambert, Katie Babin, Asuka Inoue   +2 more
exaly   +6 more sources

The Impact of Exposure Profile on the Efficacy of Dual Amylin and Calcitonin Receptor Agonist Therapy

Biomedicines, 2022
Background: Dual Amylin and Calcitonin Receptor Agonists (DACRAs) are treatment candidates for obesity and type 2 diabetes. Recently, a once-weekly DACRA (KBP-A) showed promise, potentially due to its different exposure profile compared to daily DACRA ...
Nina Sonne, Anna Thorsø Larsen, Morten Asser Karsdal, Kim Henriksen   +3 more
doaj   +3 more sources

The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile [PDF]

BMC Endocrine Disorders, 2021
Background Weight loss therapy is becoming more and more important, and two classes of molecules, namely amylin receptor and GLP-1 receptor agonists, have shown promise in this regard.
Anna Thorsø Larsen, Sofie Gydesen, Nina Sonne, Morten Asser Karsdal, Kim Henriksen   +4 more
doaj   +3 more sources

The Calcitonin Receptor Plays a Major Role in Glucose Regulation as a Function of Dual Amylin and Calcitonin Receptor Agonist Therapy [PDF]

The Journal of Pharmacology and Experimental Therapeutics, 2020
Amylin treatment improves body weight and glucose control, although it is limited by a short action and need for high doses. Dual amylin and calcitonin receptor agonists (DACRAs) are dual amylin and calcitonin receptor agonists with beneficial effects beyond those of amylin. However, to what extent the additional benefits reside in their higher potency
Anna Thorsø Larsen, Nina Sonne, Kim Vietz Andreassen, Morten Asser Karsdal, Kim Henriksen   +4 more
openaire   +5 more sources

History of current non-insulin medications for diabetes mellitus [PDF]

Journal of Community Hospital Internal Medicine Perspectives, 2012
This article is a brief review of the current non-insulin agents for diabetes mellitus in the United States, namely, sulfonylureas, biguanides, thiazolidinediones, meglitinides, α-glucosidase inhibitors, glucacon-like peptide-1 receptor agonists ...
Celeste C. L. Quianzon, Issam E. Cheikh
doaj   +1 more source

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease

Molecular Metabolism, 2021
Background: Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved to treat type 2 diabetes and obesity. They elicit robust improvements in glycemic control and weight loss, combined with cardioprotection in individuals at risk of or with pre ...
Laurie L. Baggio, Daniel J. Drucker
doaj   +1 more source

Development of High Affinity Calcitonin Analog Fragments Targeting Extracellular Domains of Calcitonin Family Receptors

Biomolecules, 2021
The calcitonin and amylin receptors (CTR and AMY receptors) are the drug targets for osteoporosis and diabetes treatment, respectively. Salmon calcitonin (sCT) and pramlintide were developed as peptide drugs that activate these receptors.
Sangmin Lee
doaj   +1 more source

Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat

Frontiers in Endocrinology, 2021
The hormones amylin and calcitonin interact with receptors within the same family to exert their effects on the human organism. Calcitonin, derived from thyroid C cells, is known for its inhibitory effect on osteoclasts.
David S. Mathiesen, Asger Lund, Tina Vilsbøll, Tina Vilsbøll, Tina Vilsbøll, Filip K. Knop, Filip K. Knop, Filip K. Knop, Filip K. Knop, Jonatan I. Bagger, Jonatan I. Bagger   +10 more
doaj   +1 more source

Insight into the role of the gut-brain axis in alcohol-related responses: Emphasis on GLP-1, amylin, and ghrelin

Frontiers in Psychiatry, 2023
Alcohol use disorder (AUD) contributes substantially to global morbidity and mortality. Given the heterogenicity of this brain disease, available pharmacological treatments only display efficacy in sub-set of individuals.
Maximilian Tufvesson-Alm, Olesya T. Shevchouk, Elisabet Jerlhag   +2 more
doaj   +1 more source

The combination of a glucagon-like peptide-1 and amylin receptor agonists reduces alcohol consumption in both male and female rats. [PDF]

Acta Neuropsychiatr
Abstract Objective: Combining different pharmaceuticals may be beneficial when treating disorders with complex neurobiology, including alcohol use disorder (AUD). The gut-brain peptides amylin and GLP-1 may be of potential interest as they individually reduce alcohol intake in rodents.
Aranäs C, Edvardsson CE, Zentveld L, Vallöf D, Witley S, Tufvesson-Alm M, Shevchouk OT, Vestlund J, Jerlhag E.   +8 more
europepmc   +3 more sources